Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PT199 |
Synonyms | |
Therapy Description |
PT199 is a monoclonal antibody that targets CD73, which potentially results in increased antitumor immune activity (Cancer Res (2022) 82 (12_Supplement): 4259; NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PT199 | PT-199|PT 199 | CD73 Antibody 12 | PT199 is a monoclonal antibody that targets CD73, which potentially results in increased antitumor immune activity (Cancer Res (2022) 82 (12_Supplement): 4259; NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05431270 | Phase I | PT199 PT199 + unspecified PD-1 antibody | Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor | Recruiting | USA | 0 |